Autolus Raises 2026 AUCATZYL Revenue Outlook to at Least $150 Million

Autolus Therapeutics plc (Nasdaq: AUTL) now expects AUCATZYL to generate at least $150 million in net product revenue in 2026, lifting its outlook to the top of its previous $140 million to $150 million range. Third-quarter net product revenue from the therapy rose 95% year over year to $41.2 million.

AUCATZYL is Autolus’ marketed therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The new full-year outlook sets a minimum, rather than a single revenue estimate.

Autolus plans to present initial clinical data from its BOBCAT Phase 1 trial in progressive multiple sclerosis at the ECTRIMS Global meeting in October 2027. The company expects the first 12 patients dosed to have at least 12 months of follow-up by the presentation, with data from as many as 24 patients available.

The presentation timing was moved after feedback at an ACTRIMS/ECTRIMS meeting in late October indicated that longer follow-up was needed to assess clinical benefit in progressive MS. The October 2027 meeting is the planned venue for the initial data presentation.